Want to see CH:COPN full AI Analyst Report?
Top Page
COSMO Pharmaceuticals N.V.
(COPN)
Select Model
Select Model
Rating:53Neutral
Price Target:
CHF65.00
▲(2.20% Upside)
Action:Reiterated
Date:07/25/26
The score is held back primarily by unstable operating performance and a swing to negative operating/free cash flow in the latest year, alongside a bearish technical trend (price below key moving averages with negative MACD). A strong, conservative balance sheet and a moderate dividend yield partially offset these risks but do not fully outweigh the recent profitability and cash-flow deterioration.
Positive Factors
Conservative balance sheet
Very low debt ratios and substantial equity (~482M) provide durable financial flexibility. Over a 2–6 month horizon this conservatism supports continued R&D, potential milestone-funded programs, dividend continuity and the ability to absorb operational shocks without immediate external financing.
Negative Factors
Sharp revenue decline in 2025
A >40% revenue drop materially weakens the business base and reduces operating leverage. Such a large structural decline compresses margins, complicates forecasting and may require cost restructuring or renewed partner efforts to restore sustainable top-line levels over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low debt ratios and substantial equity (~482M) provide durable financial flexibility. Over a 2–6 month horizon this conservatism supports continued R&D, potential milestone-funded programs, dividend continuity and the ability to absorb operational shocks without immediate external financing.
Read all positive factors
COSMO Pharmaceuticals N.V. (COPN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.03B
Dividend Yield3.25%
Average Volume (3M)19.52K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-44.72%
EPS Growth-110.73%
CountryCH
Employees325
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF115.00Price Target Upside80.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.44M
COSMO Pharmaceuticals N.V. Business Overview & Revenue Model
Company Description
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/...
How the Company Makes Money
Cosmo generates revenue primarily through (1) sales of its own commercialized products and (2) partnering/licensing arrangements in which other pharmaceutical companies commercialize Cosmo-originated products in specific territories or indications...
COSMO Pharmaceuticals N.V. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.69M | 104.85M | 266.79M | 92.78M | 102.09M | 65.07M |
| Gross Profit | 46.74M | 48.78M | 246.92M | 53.44M | 83.33M | 49.93M |
| EBITDA | -636.78K | 2.36M | 165.71M | 19.70M | 46.74M | 17.81M |
| Net Income | -6.35M | -3.63M | 133.24M | -4.93M | 17.23M | 21.67M |
Balance Sheet | ||||||
| Total Assets | 695.64M | 612.16M | 646.77M | 553.98M | 759.59M | 805.56M |
| Cash, Cash Equivalents and Short-Term Investments | 195.28M | 122.66M | 142.96M | 50.27M | 240.95M | 222.21M |
| Total Debt | 4.33M | 4.26M | 2.20M | 1.84M | 173.60M | 169.92M |
| Total Liabilities | 121.91M | 123.36M | 141.68M | 124.94M | 295.80M | 292.88M |
| Stockholders Equity | 567.02M | 481.92M | 498.33M | 422.16M | 456.93M | 505.28M |
Cash Flow | ||||||
| Free Cash Flow | -23.82M | -15.85M | 156.76M | 18.31M | 25.92M | 4.11M |
| Operating Cash Flow | -20.08M | -11.62M | 162.41M | 22.71M | 33.23M | 12.61M |
| Investing Cash Flow | -95.36M | 49.85M | -128.88M | 42.30M | 1.69M | 24.86M |
| Financing Cash Flow | 94.90M | -24.61M | -40.22M | -211.27M | -46.13M | -27.25M |
COSMO Pharmaceuticals N.V. Technical Analysis
Negative
63.60
Price Trends
65.56
Negative
73.87
Negative
83.40
Negative
Market Momentum
-1.54
Negative
42.18
Neutral
65.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:COPN, the sentiment is Negative. The current price of 63.6 is above the 20-day moving average (MA) of 62.13, below the 50-day MA of 65.56, and below the 200-day MA of 83.40, indicating a bearish trend. The MACD of -1.54 indicates Negative momentum. The RSI at 42.18 is Neutral, neither overbought nor oversold. The STOCH value of 65.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:COPN.
COSMO Pharmaceuticals N.V. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | CHF646.31M | 20.00 | ― | ― | 11.43% | -48.80% | |
66 Neutral | CHF4.01B | 25.34 | ― | 2.88% | 6.48% | -17.25% | |
62 Neutral | CHF31.96B | 59.99 | 10.09% | 1.26% | 0.81% | 165.32% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | CHF1.03B | -168.16 | 11.46% | 3.11% | -44.72% | -110.73% | |
45 Neutral | CHF1.78B | -4.80 | ― | ― | -8.06% | -87.00% |
* General Sector Average
CH:COPN
COSMO Pharmaceuticals N.V.
60.00
5.24
9.57%
CH:BSLN
Basilea Pharmaceutica
53.00
1.30
2.51%
CH:IDIA
Idorsia Ltd
6.29
3.71
143.80%
CH:SDZ
Sandoz Group Ltd
73.72
26.91
57.48%
CH:GALE
Galenica AG
80.85
-3.06
-3.64%
CH:BIOV
BioVersys AG
26.50
-0.80
-2.93%
COSMO Pharmaceuticals N.V. Corporate Events
Cosmo lifts recurring revenues and advances dermatology and GI pipelines
Jul 23, 2026
Cosmo reported strong first-half 2026 results, with recurring revenues up 18% year-on-year, driven by 38% growth from Winlevi, 35% from Lialda and 14% from its CDMO segment, and it reiterated full-year guidance. The group ended the period debt-fre...
Cosmo sets date for 2026 half-year results and investor webcast
Jul 1, 2026
Cosmo Pharmaceuticals will publish its 2026 half-year results and report on 23 July, with the documents available online from early morning. The company will host a live conference call and audio webcast that afternoon, offering investors, analyst...
Cosmo accelerates European rollout of first-in-class acne drug Winlevi
Jun 15, 2026
Cosmo Pharmaceuticals has expanded the European rollout of its acne treatment Winlevi, with market launches in Austria and Germany via distribution partner InfectoPharm, following EU approval in late 2025. As exclusive manufacturer, Cosmo is prepa...
Cosmo and Glenmark roll out first-in-class acne drug Winlevi across key European markets
Jun 11, 2026
Cosmo Pharmaceuticals’ dermatology unit Cassiopea has developed Winlevi, a first-in-class topical acne therapy based on the androgen receptor inhibitor clascoterone, and retains European rights while Cosmo serves as exclusive manufacturer. T...
Cosmo completes Phase II recruitment for novel ulcerative colitis therapy
May 18, 2026
Cosmo Pharmaceuticals has completed patient recruitment for a Phase II trial of its Rifamycin enema, an investigational treatment for distal ulcerative colitis and ulcerative proctitis, enrolling 77 patients across 24 European sites. The study wil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.